Current Report Filing (8-k)
13 July 2022 - 7:01AM
Edgar (US Regulatory)
0001415684
false
0001415684
2022-07-07
2022-07-07
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (date of earliest event reported) July 7, 2022
MusclePharm
Corporation
(Exact
name of registrant as specified in its charter)
Nevada |
|
000-53166 |
|
77-0664193 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
6728
W. Sunset Rd., Ste. 130, Las Vegas, NV 89118
(Address
of principal executive offices) (Zip Code)
(800)
859-3010
(Registrant’s
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrants under
any of the following provisions:
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: None
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
July 6, 2022, Sabina Rizvi notified the Board of Directors (the “Board”) of MusclePharm Corporation (the “Company”)
of her resignation as President and Chief Financial Officer of the Company, effective July 22, 2022.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
MUSCLEPHARM CORPORATION |
|
|
|
Date: July 12, 2022 |
By: |
/s/ Ryan
Drexler |
|
Name: |
Ryan Drexler |
|
Title: |
Chief Executive Officer |
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Muscle Pharm (CE) (USOTC:MSLP)
Historical Stock Chart
From Jul 2023 to Jul 2024